RxDoctor Payments Data

Carolann Sheaffer-Hoffman

Medical · Charlevoix, MINPI 1699487900

Payments from drug & device makers

$753in general payments, 2019–2025

Across 25 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$211
  • Novo Nordisk$168
  • Vanda Pharmaceuticals Inc.$137
  • AbbVie$131
  • Corium, LLC$26
  • Supernus Pharmaceuticals, Inc.$25
  • plus $55 from 3 others

What the payments were for

  • Food & beverage$753100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$753 in reported general payments places this provider in the 60th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$19,989
Medicare patients
168
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$42,679
XareltoRivaroxaban24$24,363
JardianceEmpagliflozin23$23,589
JanuviaSitagliptin Phosphate24$19,914
TrulicityDulaglutide22$19,476
OzempicSemaglutide14$12,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,066
FarxigaDapagliflozin Propanediol11$9,867
Bydureon BciseExenatide Microspheres12$8,841
Atorvastatin Calcium208$2,293
Lisinopril131$1,515
Doxepin Hcl13$1,512
Venlafaxine Hcl ErVenlafaxine Hcl42$1,511
Gabapentin62$1,450
Losartan Potassium93$1,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$42,67949 claims
Novo NordiskOzempic$168$12,77014 claims
AbbVieArmour Thyroid$131$95514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 755 medical providers in Michigan.

Other medical in Charlevoix

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →